Evommune (EVMN) FCF Margin (2025)

Evommune's (EVMN) quarterly FCF Margin came in at 796.63% in Q1 2025.

Evommune (EVMN) FCF Margin (2025) Analysis & Trends

Evommune (EVMN) has 1 years of FCF Margin data on file, last reported at 796.63% in Q1 2025.

On a quarterly basis, FCF Margin changed N/A year-over-year to 796.63% in Q1 2025; TTM through Mar 2026 was 523.41%, a N/A change from a year earlier, with the FY2025 full-year figure at 588.28%, up 24434.0% from the prior year.
FCF Margin for Q1 2025 stood at 796.63%.
Over the last five years, FCF Margin for EVMN reached as high as 796.63% in Q1 2025 and fell as low as 796.63% in Q1 2025.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	10.45%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	43.35%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	23.53%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Evommune	381.48 Mn	170.02 Mn	-	-

Historic Data

Download Data

Date	Value
Mar 31, 2025	-796.63%